<DOC>
	<DOC>NCT02146391</DOC>
	<brief_summary>This study is an open-label, randomized, single-center, single-dose, two-way crossover study of the PK properties of Androxal in healthy male subjects. Twelve male subjects will each receive a single dose of Androxal 25 mg in both the fed and fasting state.</brief_summary>
	<brief_title>Study to Evaluate the Effect of Food Upon the Pharmacokinetics of Androxal</brief_title>
	<detailed_description />
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<criteria>1. Speak, read, and understand English or Spanish and is willing and able to provide written informed consent on an IRBapproved form prior to the initiation of any study procedures; 2. Male; age 1860 with a BMI of 2542 kg/m2 inclusive 3. No significant abnormal findings at the screening physical examination as evaluated by the Investigator; 4. Normal laboratory values (or abnormal but not clinically significant) at screening as determined by the Investigator; 5. Subject is willing to remain in the clinic for the screening visit and 2 overnight treatment visits (approximately 36 hours for the treatment visit) 6. Must be able to swallow gelatin capsules; 7. Must be willing to remain in the clinic for the treatment visits 1. Known hypersensitivity to Clomid; 2. Abnormal screening visit vital signs or clinical laboratory evaluation considered clinically significant by the Investigator; 3. A hematocrit &gt;54% or a hemoglobin &gt;17 g/dL. 4. Subject with a significant organ abnormality or disease as determined by the Investigator; 5. Any medical condition that would interfere with the study as determined by the Investigator; 6. Participation in a clinical trial with investigational medication within 30 days prior to study medication administration; 7. An acute illness within 5 days of study medication administration; 8. Positive urine drug screen at the screening visit; 9. Known history of HIV and/or Hepatitis B or C 10. Tobacco (nicotine products) use in the 3 months prior to the study; 11. A mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study and/or evidence of an uncooperative attitude, as determined by the Investigator; 12. History of venous thromboembolic disease (e.g. deep vein thrombosis or pulmonary embolism); 13. History of myocardial infarction, unstable angina, symptomatic heart failure, ventricular dysrhythmia, or known history of QTc interval prolongation; 14. An employee or family member of an employee of the study site or the Sponsor; 15. Previous participation in a clinical study of Androxal.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>